These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 7768758)

  • 1. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.
    Johnson EM; Warnock DW; Luker J; Porter SR; Scully C
    J Antimicrob Chemother; 1995 Jan; 35(1):103-14. PubMed ID: 7768758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis.
    Cartledge JD; Midgley J; Gazzard BG
    AIDS; 1997 Dec; 11(15):1839-44. PubMed ID: 9412702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients.
    Chavanet P; Lopez J; Grappin M; Bonnin A; Duong M; Waldner A; Buisson M; Camerlynck P; Portier H
    AIDS; 1994 Jul; 8(7):945-50. PubMed ID: 7946104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
    Tumbarello M; Caldarola G; Tacconelli E; Morace G; Posteraro B; Cauda R; Ortona L
    J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient.
    White TC; Pfaller MA; Rinaldi MG; Smith J; Redding SW
    Oral Dis; 1997 May; 3 Suppl 1():S102-9. PubMed ID: 9456667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis.
    Barchiesi F; Arzeni D; Del Prete MS; Sinicco A; Falconi Di Francesco L; Pasticci MB; Lamura L; Nuzzo MM; Burzacchini F; Coppola S; Chiodo F; Scalise G
    J Antimicrob Chemother; 1998 May; 41(5):541-8. PubMed ID: 9630407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis.
    Müller FM; Weig M; Peter J; Walsh TJ
    J Antimicrob Chemother; 2000 Aug; 46(2):338-40. PubMed ID: 10933673
    [No Abstract]   [Full Text] [Related]  

  • 8. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.
    Ruhnke M; Eigler A; Tennagen I; Geiseler B; Engelmann E; Trautmann M
    J Clin Microbiol; 1994 Sep; 32(9):2092-8. PubMed ID: 7814530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis: cross resistance to itraconazole and ketoconazole].
    Metzger S; Hofmann H
    Mycoses; 1997; 40 Suppl 1():56-63. PubMed ID: 9417515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
    Khedri S; Santos ALS; Roudbary M; Hadighi R; Falahati M; Farahyar S; Khoshmirsafa M; Kalantari S
    Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.
    Sanglard D; Kuchler K; Ischer F; Pagani JL; Monod M; Bille J
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2378-86. PubMed ID: 8585712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
    Martinez M; López-Ribot JL; Kirkpatrick WR; Coco BJ; Bachmann SP; Patterson TF
    J Clin Microbiol; 2002 Sep; 40(9):3135-9. PubMed ID: 12202543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity in antifungal susceptibility of clones of Candida albicans isolated on single and sequential visits from a HIV-infected southern Chinese cohort.
    Samaranayake YH; Samaranayake LP; Tsang PC; Wong KH; Yeung KW
    J Oral Pathol Med; 2001 Jul; 30(6):336-46. PubMed ID: 11459319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).
    Zida A; Yacouba A; Bamba S; Sangare I; Sawadogo M; Guiguemde T; Kone S; Traore LK; Ouedraogo-Traore R; Guiguemde RT
    J Mycol Med; 2017 Dec; 27(4):469-475. PubMed ID: 28754462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to fluconazole in Candida albicans clinical isolates from Iranian HIV-infected patients with oropharyngeal candidiasis.
    Salari S; Khosravi AR; Mousavi SA; Nikbakht-Brojeni GH
    J Mycol Med; 2016 Mar; 26(1):35-41. PubMed ID: 26627124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients.
    Rodríguez-Tudela JL; Martínez-Suárez JV; Dronda F; Laguna F; Chaves F; Valencia E
    J Antimicrob Chemother; 1995 Jun; 35(6):793-804. PubMed ID: 7559191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.
    Anil S; Ellepola AN; Samaranayake LP
    J Oral Pathol Med; 2001 Sep; 30(8):481-8. PubMed ID: 11545239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy.
    Heald AE; Cox GM; Schell WA; Bartlett JA; Perfect JR
    AIDS; 1996 Mar; 10(3):263-8. PubMed ID: 8882665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis.
    Martínez M; López-Ribot JL; Kirkpatrick WR; Bachmann SP; Perea S; Ruesga MT; Patterson TF
    J Antimicrob Chemother; 2002 Mar; 49(3):515-24. PubMed ID: 11864952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.
    Moran GP; Sullivan DJ; Henman MC; McCreary CE; Harrington BJ; Shanley DB; Coleman DC
    Antimicrob Agents Chemother; 1997 Mar; 41(3):617-23. PubMed ID: 9056003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.